News und Analysen
![Quidel to Present at Upcoming Conferences](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Quidel to Present at Upcoming Conferences
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
![Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Humana Pharmacy Wins Surescripts 2019 White Coat Award™ For Prescription Accuracy
Humana Pharmacy, the mail-delivery pharmacy service of Humana Inc. (NYSE: HUM), has won the prestigious 2019 Surescripts White Coat Award, an honor that celebrates healthcare industry leaders
![Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Humana Is No. 1 in Customer Service Among Health Insurance Companies, as Ranked by Newsweek
For the second year in a row, Humana Inc. (NYSE: HUM) rose to the top as No. 1 in service in its industry, according to Newsweek’s 2020 list of America’s Best Customer Service.
“We’re proud to
![Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be
![Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Humana again gets Gold award in American Heart Association’s Workplace Health Achievement Index
For the third year in a row, Humana Inc. (NYSE: HUM) has achieved top Gold-level recognition in the American Heart Association’s Workplace Health Achievement Index, a science-based assessment that
![Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic
![Dexcom Announces Upcoming Conference Presentation](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Steven Pacelli, Executive Vice President, Strategy and
![Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019
Veeva Systems (NYSE:VEEV) will announce financial results for its third quarter which ended October 31, 2019 after the market close on November 26, 2019. Veeva will host a conference call and
![Almirall Makes Shift to Specialty Medicine with Veeva CRM](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Almirall Makes Shift to Specialty Medicine with Veeva CRM
Veeva Systems (NYSE:VEEV) today announced that Almirall selected multichannel Veeva CRM to deliver seamless customer experience across all channels as it shifts business focus to specialty
![Veeva Completes Acquisition of Crossix](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Veeva Completes Acquisition of Crossix
Veeva Systems (NYSE:VEEV) today announced it has completed its acquisition of Crossix Solutions. Trusted by more than 200 pharmaceutical brands, Crossix provides privacy-safe U.S. patient data and
![Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed
Waters Corporation (NYSE:WAT) announced today that its ACQUITY™ Advanced Polymer Chromatography™ (APC™) System is the first fully solvent-compatible UltraPerformance Liquid Chromatography
![Dexcom Reports Third Quarter 2019 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom Reports Third Quarter 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.
Third Quarter 2019 Highlights:
-
Revenue grew 49% versus the same quarter of
![Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/
Dr. Howard Mayer, Executive Vice-President and Head
![Agilent Named One of Top 10 Best Workplaces in Singapore](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Agilent Named One of Top 10 Best Workplaces in Singapore
Agilent Technologies, Inc. (NYSE: A) today announced it has been named among the top 10 Best Workplaces™ in Singapore for 2019 by the Great Place to Work® (GPTW) Institute. Agilent was selected as
![CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
CORRECTING and REPLACING Agilent Technologies to Host Conference Call to Review Fourth Quarter Fiscal Year 2019 Financial Results; Announces Schedule for Upcoming Webcasts
![Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!
Einer der größten Gewinner am US-Aktienmarkt war gestern das Papier von Biogen (WKN: 789617). Grund hierfür waren jedoch nicht in erster Linie die vorgelegten, sehr guten Quartalszahlen, sondern
![FMC: Es ist wieder mal Zeit für Skandale!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
FMC: Es ist wieder mal Zeit für Skandale!
Dass Aktien von Fresenius Medical Care (WKN: 578580) in der laufenden Woche zu den größten Verlierern im DAX gehören – seit Montag steht ein Minus von -4,26% zu Buche – ist wohl maßgeblich auf
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: Allergan plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: Allergan plc
![DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19
![DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19 http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--30a4f87e2f6442a34d491960296cefece4f65ecc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/carl_zeiss_meditec_logogif.png?locale=de)
DGAP-Adhoc: Carl Zeiss Meditec AG erzielt deutliche Zuwächse bei Umsatz und Ergebnis im Geschäftsjahr 2018/19
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)